Roche's Genentech and Sangamo Therapeutics, a gene therapy company, signed an agreement to develop AAV gene therapy for neurodegenerative diseases, including Alzheimer's disease. The deal is worth nearly $2 billion, including a $50 million payment to Sangamo in the near term.
罗氏签署20亿美元协议布局阿尔茨海默疗法
Roche signed a $2 billion agreement to lay out Alzheimer's disease therapy.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.